IGMSUnknownNano-Cap
IGM Biosciences, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for IGM Biosciences, Inc. (IGMS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are IGMS insiders buying or selling?
IGM Biosciences, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since September 2019, Trabud has recorded 146 Form 4 filings for IGMS: 31 buys ($194.6M) and 115 sells ($6.9M).
Source: SEC EDGAR Form 4
Key Statistics (September 2019 – Jul 25, 2025)
Total Form 4 filings
146
SEC EDGAR
Insider filers
17
Insider buys (31)
$194.6M
Insider sells (115)
$6.9M
Insider sentiment
Net buyingNet insider flow of $187.7M in net buying since September 2019.
Recent IGMS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 25, 2025 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sale | 8.7K | $1.27 | $11.1K | SEC ↗ |
| Jul 25, 2025 | Mary Beth Harler | Chief Executive Officer | Sale | 14.5K | $1.27 | $18.5K | SEC ↗ |
| Jul 25, 2025 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sale | 4.4K | $1.27 | $5.6K | SEC ↗ |
| Jun 21, 2025 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sale | 486 | $1.20 | $582.81 | SEC ↗ |
| Jun 21, 2025 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sale | 1.5K | $1.20 | $1.8K | SEC ↗ |
| Jun 21, 2025 | Mary Beth Harler | Chief Executive Officer | Sale | 1.5K | $1.20 | $1.8K | SEC ↗ |
| Jun 21, 2025 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sale | 951 | $1.20 | $1.1K | SEC ↗ |
| May 16, 2025 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.9K | $1.12 | $2.1K | SEC ↗ |
| Mar 18, 2025 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.7K | $1.23 | $2.1K | SEC ↗ |
| Mar 18, 2025 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sale | 7.3K | $1.23 | $9.0K | SEC ↗ |
| Mar 18, 2025 | Mary Beth Harler | Chief Executive Officer | Sale | 7.3K | $1.23 | $9.0K | SEC ↗ |
| Mar 18, 2025 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sale | 4.5K | $1.23 | $5.5K | SEC ↗ |
| Jan 17, 2025 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.1K | $1.70 | $1.9K | SEC ↗ |
| Dec 19, 2024 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sale | 539 | $7.48 | $4.0K | SEC ↗ |
| Dec 19, 2024 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sale | 1.1K | $7.48 | $8.0K | SEC ↗ |
| Dec 19, 2024 | Mary Beth Harler | Chief Executive Officer | Sale | 1.7K | $7.48 | $12.8K | SEC ↗ |
| Dec 19, 2024 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sale | 1.7K | $7.48 | $12.8K | SEC ↗ |
| Sep 18, 2024 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sale | 469 | $11.54 | $5.4K | SEC ↗ |
| Sep 18, 2024 | Chris H Takimoto | CHIEF MEDICAL OFFICER | Sale | 1.5K | $11.54 | $17.2K | SEC ↗ |
| Sep 18, 2024 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sale | 1.5K | $11.54 | $17.2K | SEC ↗ |
| Sep 18, 2024 | Fred Schwarzer | CEO AND PRESIDENT | Sale | 3.9K | $11.54 | $45.5K | SEC ↗ |
| Sep 18, 2024 | Bruce Keyt | CHIEF SCIENTIFIC OFFICER | Sale | 1.5K | $11.54 | $17.2K | SEC ↗ |
| Sep 18, 2024 | Mary Beth Harler | Head, Research & Autoimmunity | Sale | 1.5K | $11.54 | $17.2K | SEC ↗ |
| Sep 18, 2024 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sale | 925 | $11.54 | $10.7K | SEC ↗ |
| Jul 29, 2024 | Julie Hambleton | Director | Sale | 15.1K | $14.00 | $211.8K | SEC ↗ |
Showing the 25 most recent of 146 Form 4 filings for IGM Biosciences, Inc..
Most active IGMS insiders
- Bruce Keyt29 filings
- Daniel Shinyu Chen15 filings
- Lisa Lynn Decker14 filings
- Misbah Tahir13 filings
- Chris H Takimoto9 filings
Ask anything about IGMS insider activity
Use Trabud's AI agent to query IGM Biosciences, Inc.'s Form 4 history in plain English — "Show me IGMS CEO purchases this year" or compare it against any other ticker.
Open the AI agentIGMS insider trading FAQ
Are IGM Biosciences, Inc. insiders buying or selling?
IGM Biosciences, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since September 2019, Trabud has recorded 146 Form 4 filings for IGMS: 31 buys ($194.6M) and 115 sells ($6.9M). Over the full record that is net buying of $187.7M.
How many insiders trade IGMS stock?
17 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for IGM Biosciences, Inc.. The most recent filing was accepted on Jul 25, 2025.
Where does Trabud get IGMS insider trading data?
All IGMS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.